Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.
circulating cell-free DNA
circulating cell-free tumor DNA
liquid biopsy
serum tumor markers
tumor burden
tumor-volumetry
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
28
01
2019
accepted:
06
08
2019
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
23
1
2020
Statut:
ppublish
Résumé
The clinical decisions made when treating patients with metastatic cancer require knowledge of the current tumor extent and response to therapy. For the majority of solid tumors, a response assessment, which is based on imaging, is used to guide these decisions. However, measuring serum protein biomarkers (i.e. tumor markers) may be of additional use. Furthermore, tumor markers exhibit variable specificity and sensitivity and cannot therefore be solely relied upon when making decisions regarding cancer treatment. Therefore, there is a clinical requirement for the identification of specific, sensitive and quantitative biomarkers. In recent years, circulating cell-free DNA (cfDNA) and mutation-specific circulating cell-free tumor DNA (cftDNA) have been identified as novel potential biomarkers. In the current study, cfDNA and cftDNA were compared using imaging-based staging and current tumor markers in 15 patients with metastatic colorectal, pancreatic or breast cancer. These patients were treated at the Third Medical Department of Paracelsus Medical University Salzburg (Austria). The results of the current study demonstrated a statistically significant correlation between the concentration changes of cfDNA and cftDNA and response to treatment, which was assessed by imaging. A correlation was not indicated with current clinically used tumor markers, including carcinoembryonic antigen, carcinoma antigen 15-3 and carcinoma antigen 19-9. The present study also indicated a correlation between cfDNA and cftDNA and the tumor volume of metastatic lesions, which was not observed with the current clinically used tumor markers. In conclusion, cfDNA and cftDNA exhibit the potential to become novel biomarkers for the response assessment following cancer treatment, and may serve as a tool for the estimation of tumor volume. The current study further supports the increasingly important role of cfDNA and cftDNA as new monitoring tools for use during cancer therapy.
Identifiants
pubmed: 31966080
doi: 10.3892/ol.2019.11192
pii: OL-0-0-11192
pmc: PMC6956108
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1551-1558Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Curr Colorectal Cancer Rep. 2014 Dec 1;10(4):372-379
pubmed: 25395895
Minerva Chir. 2004 Apr;59(2):99-111
pubmed: 15238885
J Clin Oncol. 2007 Nov 20;25(33):5287-312
pubmed: 17954709
AJR Am J Roentgenol. 2015 Mar;204(3):W282-8
pubmed: 25714313
Cancer Res Treat. 2005 Oct;37(5):290-3
pubmed: 19956529
Pathology. 2007 Apr;39(2):197-207
pubmed: 17454749
Cancer Discov. 2013 Jul;3(7):761-9
pubmed: 23619167
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
Biochim Biophys Acta. 2014 Dec;1846(2):539-46
pubmed: 25444714
Br J Radiol. 2001 Nov;74(887):983-6
pubmed: 11709461
BMC Cancer. 2016 Jul 13;16:459
pubmed: 27411945
Lung Cancer. 2009 Apr;64(1):92-7
pubmed: 18804892
Nature. 2014 Jul 31;511(7511):524-6
pubmed: 25079538
J Opt Soc Am A Opt Image Sci Vis. 2016 Oct 1;33(10):1978-1988
pubmed: 27828101
Genome Med. 2013 Aug 13;5(8):70
pubmed: 23953663
Gastroenterology. 1997 Apr;112(4):1114-20
pubmed: 9097993
Eur J Cancer. 2016 Jul;62:138-45
pubmed: 27237360
Anticancer Res. 2003 Jul-Aug;23(4):3437-40
pubmed: 12926086
Onco Targets Ther. 2013 Jul 08;6:819-32
pubmed: 23874104
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2009 Apr 1;69(7):3060-8
pubmed: 19318552
Digestion. 1997;58(6):550-6
pubmed: 9438601
Nat Rev Cancer. 2014 Sep;14(9):623-31
pubmed: 25154812
J Thorac Oncol. 2011 Feb;6(2):286-90
pubmed: 21252717
Cell. 2017 Feb 9;168(4):742-742.e1
pubmed: 28187292
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Anticancer Res. 2010 Dec;30(12):5195-200
pubmed: 21187512
Asian Pac J Cancer Prev. 2013;14(3):1597-9
pubmed: 23679242
BMC Cancer. 2013 May 22;13:254
pubmed: 23697613
Arch Gynecol Obstet. 2013 Jan;287(1):97-102
pubmed: 22941327
Oncotarget. 2011 Mar;2(3):135-64
pubmed: 21411864
Br J Cancer. 2013 Feb 5;108(2):469-76
pubmed: 23169292
Cancer Biomark. 2010;6(3-4):211-9
pubmed: 20660966
Int J Cancer. 2003 Jan 10;103(2):149-52
pubmed: 12455027
Infect Disord Drug Targets. 2008 Jun;8(2):100-8
pubmed: 18537705
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):73-74
pubmed: 28096542
Clin Chim Acta. 2001 Nov;313(1-2):143-6
pubmed: 11694252
Turk J Gastroenterol. 2014 Apr;25(2):162-9
pubmed: 25003676
Radiologia. 2014 May-Jun;56(3):193-205
pubmed: 22902252
Cancer Sci. 2003 Nov;94(11):1015-20
pubmed: 14611681
Crit Rev Oncol Hematol. 2017 Dec;120:13-21
pubmed: 29198327
Eur Radiol. 2007 Oct;17(10):2561-71
pubmed: 17492290
Ann N Y Acad Sci. 2004 Jun;1022:xi; 1-322
pubmed: 15320312
World J Surg. 1984 Dec;8(6):808-21
pubmed: 6334938
Eur Radiol. 2010 Jun;20(6):1456-67
pubmed: 20033179
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
J Cancer Res Clin Oncol. 2010 Nov;136(11):1627-31
pubmed: 20174821
Eur J Cancer. 2005 Jul;41(10):1426-30
pubmed: 15919202
Br J Cancer. 2009 Apr 21;100(8):1330-5
pubmed: 19367287
Curr Opin Mol Ther. 2004 Jun;6(3):273-8
pubmed: 15264429
Biochim Biophys Acta. 2005 Nov 25;1756(2):97-101
pubmed: 16169155
Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S17-27
pubmed: 22443084
Virchows Arch. 2008 Nov;453(5):417-31
pubmed: 18802721
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Scand J Gastroenterol Suppl. 2003;(237):26-9
pubmed: 12797677
J Natl Cancer Inst. 2004 May 19;96(10):801-2; author reply 802
pubmed: 15150309
Genome Med. 2013 Aug 23;5(8):73
pubmed: 23998943
Genome Res. 2012 Feb;22(2):220-31
pubmed: 21990379